Chemo's impact on QoL often outweighs benefit in advanced PCa
Half of men who suffer from late-stage prostate cancer would consider chemotherapy a treatment option, and 65% believe the impact on quality of life outweighs its benefit, according to a new survey released by Us TOO International Prostate Cancer Education & Support Network.
Half of men who suffer from late-stage prostate cancer would consider chemotherapy a treatment option, and 65% believe the impact on quality of life outweighs its benefit, according to a new survey released by Us TOO International Prostate Cancer Education & Support Network.
Nearly two-thirds of patients, caregivers, and physicians surveyed were dissatisfied with the current treatment options for advanced prostate cancer. Of the late-stage patients surveyed, bone pain was the number one concern. Sixty-seven percent of the patients feared they will feel pain as their cancer progresses, and 47% of those who experienced bone pain report that they feel pain all of the time or every day.
The survey of more than 500 prostate cancer patients, caregivers, and physicians highlights the need for better treatment options for late-stage disease, Us TOO said.
